Pharmaceuticals - Bosnia and Herzegovina

  • Bosnia and Herzegovina
  • In Bosnia and Herzegovina, the revenue in the Pharmaceuticals market is projected to reach US$161.00m by 2024.
  • The largest market within this industry is Oncology Drugs, which is expected to have a market volume of US$27.59m by 2024.
  • Looking ahead, a steady annual growth rate of 4.68% is anticipated (CAGR 2024-2029), resulting in a market volume of US$202.40m by 2029.
  • When compared globally, United States is forecasted to generate the highest revenue, amounting to US$630.30bn in 2024.
  • Bosnia and Herzegovina's pharmaceutical market is experiencing a growing demand for innovative drugs and a shift towards personalized medicine.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Pharmaceuticals market in Bosnia and Herzegovina has been experiencing steady growth in recent years.

Customer preferences:
Bosnia and Herzegovina has a relatively small population, but with a high demand for pharmaceutical products due to the prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases. Customers in Bosnia and Herzegovina have a preference for generic drugs due to their affordability, which has led to an increase in the production and consumption of these drugs in the country.

Trends in the market:
The pharmaceutical industry in Bosnia and Herzegovina has been growing at a steady pace, with an increase in the number of pharmaceutical companies and the production of generic drugs. The government has been implementing policies to encourage the growth of the pharmaceutical industry in the country, such as the reduction of taxes on pharmaceutical products and the provision of subsidies for the production of generic drugs.

Local special circumstances:
The healthcare system in Bosnia and Herzegovina is decentralized, with both the Federation of Bosnia and Herzegovina and the Republika Srpska having their own healthcare systems. This has led to differences in the regulation of the pharmaceutical industry in the two entities, with the Federation of Bosnia and Herzegovina having a more centralized system. The pharmaceutical industry in Bosnia and Herzegovina is also heavily regulated, with strict requirements for the registration and marketing of pharmaceutical products.

Underlying macroeconomic factors:
The growth of the pharmaceutical industry in Bosnia and Herzegovina can be attributed to a number of macroeconomic factors. The country has a relatively low labor cost, which has made it an attractive location for pharmaceutical companies to set up production facilities. The government has also been implementing policies to attract foreign investment in the pharmaceutical industry, which has led to an increase in the number of foreign companies operating in the country. The growth of the pharmaceutical industry in Bosnia and Herzegovina has also been driven by the increasing demand for pharmaceutical products in the country, which has been fueled by the prevalence of chronic diseases.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)